Alan I. Green, M.D. is the Raymond Sobel Professor of Psychiatry, Professor of Pharmacology and Toxicology and Chairman of the Department of Psychiatry at Geisel School of Medicine at Dartmouth. Director, Dartmouth SYNERGY, The Dartmouth Clinical and Translational Science Institute.
He received his B.A. from Columbia College and his M.D. degree from the Johns Hopkins University School of Medicine. Following an internship in medicine at the Beth Israel Hospital in Boston, he was a research associate at the National Institute of Mental Health and was Director of Biomedical Research at the Special Action Office for Drug Abuse Prevention in the Executive Office of the President. He did his psychiatry residency and a clinical research fellowship at the Harvard-based Massachusetts Mental Health Center. He joined the Harvard faculty in 1984 and was Director of the Commonwealth Research Center at Harvard Medical School from 1987 until 2002. He joined the Geisel School of Medicine's Department of Psychiatry as Professor and Chairman in November 2002, and he became Director of Dartmouth SYNERGY in 2012. He has been a highly productive and active investigator, has received peer-reviewed funding throughout his career, has mentored over 30 trainees, and is the author of more than 300 papers and abstracts.
Raymond Sobel Professor of Psychiatry, Professor of Pharmacology & Toxicology, Chairman, Department of Psychiatry, Director, SYNERGY: Dartmouth Clinical and Translational Science Institute, Associate Dean for Clinical and Translational Science, Geisel School of Medicine at Dartmouth
Schizophrenia and comorbid substance use disorder: neuropharmacology, neuroimaging and treatment development Medication development for addiction Brain reward circuitry Animal models Early intervention in schizophrenia
Dr. Green's research program, which involves clinical and neurobiological studies of patients with schizophrenia, particularly those with co-occurring substance use disorders, medication development studies for patients with alcoholism, and studies of alcohol drinking animals, has been funded by a series of grants from NIH, NARSAD and industry. He and his colleagues have proposed a neurobiological model suggesting that co-occurring substance use disorder in patients with schizophrenia relates, at least in part, to deficiencies in dopamine-mediated brain reward circuits. Data from his group have suggested that the novel antipsychotic medication clozapine limits alcohol and other substance use in these patients; he has proposed that the unique effects of clozapine in these patients relates to the mechanism of action of the drug, including its effects in brain reward circuits. On-going studies are continuing to probe the optimal psychopharmacological strategies for patients with co-occurring disorders through clinical trials, neuroimaging studies in humans, and a series of pharmacologic, neuroimaging and neurostimulation investigations in animals.
R01DA032533 (Green) 07/15/2012 - 03/31/2017 NIDA Clozapine for cannabis use disorder in schizophrenia This study aims primarily to determine the comparative ability of clozapine and risperidone to decrease cannabis use in patients with schizophrenia and cannabis use disorder. Other subsidiary aims will determine the comparative effects of these medications on psychiatric symptoms, neuropsychological functioning, and quality of life. Lastly, the study will explore whether patients with the val/val genotype at the COMT val158met locus are more likely to respond to clozapine than are those with the met/met or the val/met genotype.
R01DA034699 (Green) 09/01/2013 - 03/31/2019 NIDA Cannabis, schizophrenia and reward: self-medication and agonist treatment? This study aims to assess the effects of cannabis and dronabinol on the brain reward circuit in individuals with schizophrenia and co-occurring cannabis use disorder as well as in those with cannabis use disorder alone.
1 UL1 TR001086-01 (Green) 09/26/2013 - 04/30/2018 NCATS SYNERGY| The Dartmouth Clinical and Translational Science Institute Dartmouth SYNERGY seeks to promote and substantially strengthen Dartmouth's basic, clinical, translational and outcomes research potential.
3UL1TR001086-02S2 (Green) 09/20/2014 - 08/31/2015 NCATS Development of a Cross-CTSA IRB Reliance Program (National IRB Reliance Initiative) This Supplement to Dartmouth provides for the creation of a national program of IRB Reliance across the CTSA network - with the intent of increasing the speed and efficiency of launching and monitoring multi-site clinical investigations.
3UL1TR001086-02S1 (Green) 09/05/2014 - 03/04/2015 NCATS Enhancing Clinical Research Professionals' Training and Qualifications This Supplement allows Dartmouth to participate in a national program to enhance training for Good Clinical Practice across the national CTSA consortium.
NCIG-006 (Green) 04/01/2015 - 03/22/2016 NIAAA/Fast-Track Drugs & Biologics, LLC Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT(R) (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder This study aims to assess the efficacy of gabapentin in the treatment of alcohol use disorder.
Dr. Green has been the primary research mentor for over 30 predoctoral and postdoctoral trainees. At present, he is the primary mentor for two junior investigators, two post-doctoral research fellows, and five undergraduates.
1) Medication development for alcohol drinking in rodents. 2) Neuroimaging and brain reward circuitry in schizophrenia.
Psychopharmacology Graduate and Medical Pharmacology Neuroscience of Psychiatric Disorders
Columbia College, A.B. 1965 The Johns Hopkins University School of Medicine, M.D. 1969
Department of Psychiatry, Geisel School of Medicine at Dartmouth
DHMC, 1 Medical Center Drive
Rebecca K. Paquette 603-650-7549 firstname.lastname@example.org